TY  - JOUR
AU  - Manuel Sanchez-Maldonado, Jose
AU  - Caliz, Rafael
AU  - Angel Lopez-Nevot, Miguel
AU  - Jose Cabrera-Serrano, Antonio
AU  - Moniz-Diez, Ana
AU  - Canhao, Helena
AU  - Ter Horst, Rob
AU  - Quartuccio, Luca
AU  - Sorensen, Signe B.
AU  - Glintborg, Bente
AU  - Hetland, Merete L.
AU  - Filipescu, Ileana
AU  - Perez-Pampin, Eva
AU  - Conesa-Zamora, Pablo
AU  - Swierkot, Jerzy
AU  - den Broeder, Alfons A.
AU  - De Vita, Salvatore
AU  - Brix Petersen, Eva Rabing
AU  - Li, Yang
AU  - Ferrer, Miguel A.
AU  - Escudero, Alejandro
AU  - Netea, Mihai G.
AU  - Coenen, Marieke J. H.
AU  - Andersen, Vibeke
AU  - Fonseca, Joao E.
AU  - Jurado, Manuel
AU  - Bogunia-Kubik, Katarzyna
AU  - Collantes, Eduardo
AU  - Sainz, Juan
PY  - 2021
DO  - 10.3389/fimmu.2021.672255
SN  - 1664-3224
UR  - https://hdl.handle.net/10668/25696
T2  - Frontiers in immunology
AB  - We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium...
LA  - en
PB  - Frontiers media sa
KW  - GWAS
KW  - genetic variant
KW  - rheumatoid arthritis
KW  - drug response
KW  - TNF inhibitors
KW  - Tumor-necrosis-factor
KW  - Genetic-variants
KW  - Monoclonal-antibody
KW  - Clinical register
KW  - Soluble cd5
KW  - Association
KW  - Receptors
KW  - Classification
KW  - Polymorphisms
KW  - Itolizumab
TI  - Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
TY  - research article
VL  - 12
ER  -